Tavaborole

Drug Profile

Tavaborole

Alternative Names: AN-2690; Kerydin; SCH-900340

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Anacor Pharmaceuticals
  • Class Antifungals; Organic boron compounds; Small molecules
  • Mechanism of Action Leucyl-tRNA synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Onychomycosis

Most Recent Events

  • 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
  • 29 Jun 2015 Anacor Pharmaceuticals announced an amendment to its commercialisation agreement with Sandoz
  • 07 May 2015 No recent reports on development identified - Phase-III for Onychomycosis in Mexico and Canada (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top